Treatment of Chemotherapy-Refractory DLBCL with Anti-CD19 CAR T Cells


Treatment of Chemotherapy-Refractory DLBCL with Anti-CD19 CAR T Cells
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with David L Porter, MD (3/3/14)
Kochenderfer JN et al. Effective treatment of chemotherapy-refractory diffuse large B-cell lymphoma with autologous T cells genetically-engineered to express an anti-CD19 chimeric antigen receptor. Proc ASH 2013;Abstract 168.

Dr Porter is Jodi Fisher Horowitz Professor of Leukemia Care Excellence and Director of Blood and Marrow Transplantation at the University of Pennsylvania Health System's Abramson Cancer Center in Philadelphia, Pennsylvania.